Literature DB >> 20213817

Long-term results of a multicenter study on subthalamic and pallidal stimulation in Parkinson's disease.

Elena Moro1, Andres M Lozano, Pierre Pollak, Yves Agid, Stig Rehncrona, Jens Volkmann, Jaime Kulisevsky, Jose A Obeso, Alberto Albanese, Marwan I Hariz, Niall P Quinn, Jans D Speelman, Alim L Benabid, Valerie Fraix, Alexandre Mendes, Marie-Laure Welter, Jean-Luc Houeto, Philippe Cornu, Didier Dormont, Annalena L Tornqvist, Ron Ekberg, Alfons Schnitzler, Lars Timmermann, Lars Wojtecki, Andres Gironell, Maria C Rodriguez-Oroz, Jorge Guridi, Anna R Bentivoglio, Maria F Contarino, Luigi Romito, Massimo Scerrati, Marc Janssens, Anthony E Lang.   

Abstract

We report the 5 to 6 year follow-up of a multicenter study of bilateral subthalamic nucleus (STN) and globus pallidus internus (GPi) deep brain stimulation (DBS) in advanced Parkinson's disease (PD) patients. Thirty-five STN patients and 16 GPi patients were assessed at 5 to 6 years after DBS surgery. Primary outcome measure was the stimulation effect on the motor Unified Parkinson's Disease Rating Scale (UPDRS) assessed with a prospective cross-over double-blind assessment without medications (stimulation was randomly switched on or off). Secondary outcomes were motor UPDRS changes with unblinded assessments in off- and on-medication states with and without stimulation, activities of daily living (ADL), anti-PD medications, and dyskinesias. In double-blind assessment, both STN and GPi DBS were significantly effective in improving the motor UPDRS scores (STN, P < 0.0001, 45.4%; GPi, P = 0.008, 20.0%) compared with off-stimulation, regardless of the sequence of stimulation. In open assessment, both STN- and GPi-DBS significantly improved the off-medication motor UPDRS when compared with before surgery (STN, P < 0.001, 50.5%; GPi, P = 0.002, 35.6%). Dyskinesias and ADL were significantly improved in both groups. Anti-PD medications were significantly reduced only in the STN group. Adverse events were more frequent in the STN group. These results confirm the long-term efficacy of STN and GPi DBS in advanced PD. Although the surgical targets were not randomized, there was a trend to a better outcome of motor signs in the STN-DBS patients and fewer adverse events in the GPi-DBS group. (c) 2010 Movement Disorder Society.

Entities:  

Mesh:

Year:  2010        PMID: 20213817     DOI: 10.1002/mds.22735

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  117 in total

1.  Parkinson disease: deep brain stimulation versus best medical therapy for PD.

Authors:  Matthew A Brodsky; John G Nutt
Journal:  Nat Rev Neurol       Date:  2010-10       Impact factor: 42.937

2.  Motor follow-up of parkinsonian patients after deep-brain stimulation.

Authors:  Giovanni Caranci; Francesco Lena; Nicola Modugno; Stefano Ruggieri; Pantaleo Romanelli; Mario Manfredi
Journal:  Neurol Sci       Date:  2010-07-22       Impact factor: 3.307

3.  Stuck in a rut: rethinking depression and its treatment.

Authors:  Paul E Holtzheimer; Helen S Mayberg
Journal:  Trends Neurosci       Date:  2010-11-08       Impact factor: 13.837

Review 4.  High frequency deep brain stimulation of the subthalamic nucleus versus continuous subcutaneous apomorphine infusion therapy: a review.

Authors:  R Carron; V Fraix; C Maineri; E Seigneuret; B Piallat; P Krack; P Pollak; A L Benabid; Stéphan Chabardès
Journal:  J Neural Transm (Vienna)       Date:  2010-12-29       Impact factor: 3.575

5.  Parkinson disease: deep brain stimulation in Parkinson disease-what went wrong?

Authors:  Paul Krack; Marwan I Hariz
Journal:  Nat Rev Neurol       Date:  2010-10       Impact factor: 42.937

6.  Randomized trial of deep brain stimulation for Parkinson disease: thirty-six-month outcomes.

Authors:  Frances M Weaver; Kenneth A Follett; Matthew Stern; Ping Luo; Crystal L Harris; Kwan Hur; William J Marks; Johannes Rothlind; Oren Sagher; Claudia Moy; Rajesh Pahwa; Kim Burchiel; Penelope Hogarth; Eugene C Lai; John E Duda; Kathryn Holloway; Ali Samii; Stacy Horn; Jeff M Bronstein; Gatana Stoner; Philip A Starr; Richard Simpson; Gordon Baltuch; Antonio De Salles; Grant D Huang; Domenic J Reda
Journal:  Neurology       Date:  2012-06-20       Impact factor: 9.910

Review 7.  Parkinson's disease therapeutics: new developments and challenges since the introduction of levodopa.

Authors:  Yoland Smith; Thomas Wichmann; Stewart A Factor; Mahlon R DeLong
Journal:  Neuropsychopharmacology       Date:  2011-09-28       Impact factor: 7.853

Review 8.  Current Practice and the Future of Deep Brain Stimulation Therapy in Parkinson's Disease.

Authors:  Leonardo Almeida; Wissam Deeb; Chauncey Spears; Enrico Opri; Rene Molina; Daniel Martinez-Ramirez; Aysegul Gunduz; Christopher W Hess; Michael S Okun
Journal:  Semin Neurol       Date:  2017-05-16       Impact factor: 3.420

9.  STN vs. GPi Deep Brain Stimulation: Translating the Rematch into Clinical Practice.

Authors:  Nolan R Williams; Kelly D Foote; Michael S Okun
Journal:  Mov Disord Clin Pract       Date:  2014-04-01

Review 10.  Systems approaches to optimizing deep brain stimulation therapies in Parkinson's disease.

Authors:  Sabato Santaniello; John T Gale; Sridevi V Sarma
Journal:  Wiley Interdiscip Rev Syst Biol Med       Date:  2018-03-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.